Insider Selling: Natera (NASDAQ:NTRA) Insider Sells $263,094.90 in Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 1,010 shares of the firm’s stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $260.49, for a total transaction of $263,094.90. Following the transaction, the insider owned 133,633 shares in the company, valued at approximately $34,810,060.17. This trade represents a 0.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Solomon Moshkevich also recently made the following trade(s):

• On Tuesday, July 28th, Solomon Moshkevich sold 1,204 shares of Natera stock. The shares were sold at an average price of $254.07, for a total transaction of $305,900.28.
• On Wednesday, July 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $272.90, for a total transaction of $818,700.00.
• On Monday, June 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $218.43, for a total transaction of $655,290.00.
• On Tuesday, May 26th, Solomon Moshkevich sold 1,652 shares of Natera stock. The shares were sold at an average price of $202.84, for a total transaction of $335,091.68.
• On Friday, May 1st, Solomon Moshkevich sold 3,405 shares of Natera stock. The shares were sold at an average price of $203.69, for a total transaction of $693,564.45.

Natera Stock Performance

Shares of NTRA opened at $267.76 on Friday. Natera, Inc. has a fifty-two week low of $131.81 and a fifty-two week high of $288.04. The company has a market capitalization of $38.35 billion, a price-to-earnings ratio of -164.27 and a beta of 1.51. The firm has a 50-day simple moving average of $246.77 and a 200-day simple moving average of $222.22.

Institutional Investors Weigh In On Natera

A number of hedge funds have recently added to or reduced their stakes in NTRA. Elevation Wealth Partners LLC purchased a new stake in Natera in the 2nd quarter valued at approximately $30,000. Reflection Asset Management purchased a new position in shares of Natera during the 4th quarter worth approximately $29,000. Palladiem LLC acquired a new stake in shares of Natera in the 4th quarter valued at approximately $31,000. Bank of Jackson Hole Trust lifted its holdings in shares of Natera by 103.8% in the 4th quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock valued at $37,000 after buying an additional 83 shares during the period. Finally, International Assets Investment Management LLC boosted its stake in shares of Natera by 132.9% in the first quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock valued at $35,000 after buying an additional 97 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. The Goldman Sachs Group began coverage on Natera in a research report on Friday, June 5th. They set a “neutral” rating and a $245.00 price objective for the company. Wells Fargo & Company boosted their target price on Natera from $215.00 to $220.00 and gave the company an “equal weight” rating in a report on Friday, May 8th. Zacks Research cut Natera from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. JPMorgan Chase & Co. increased their price target on Natera from $260.00 to $265.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $249.00 price objective on shares of Natera in a research report on Tuesday, May 12th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Natera has a consensus rating of “Moderate Buy” and an average price target of $267.83.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.